Paratek Pharmaceuticals — Transcept Pharmaceuticals — Investor Presentation (March 2012)
23 slides from Paratek Pharmaceuticals's investor presentation, Mar 13, 2012
Slide 1: Specialty pharmaceutical company focused on neuroscience
Exhibit 99.1 A specialty pharmaceutical company focused on the development and commercialization of proprietary products to address important therapeutic needs in the field of neuroscience March 2012
Slide 2: Forward looking statements
Forward looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. Examples of such statements include our expectat
Slide 3: Transcept: preparing for Intermezzo commercialization
Transcept: preparing for Intermezzo ® commercialization Therapeutic focus Neuroscience / psychiatry Large markets, Intermezzo: middle of the night awakenings unmet needs TO-2061 : treatment resistant OCD Commercial U.S. primary care partnership: Purdue Pharma platform Option to co-promote Intermezzo
Slide 4: Intermezzo (zolpidem tartrate) sublingual tablet
Intermezzo® (zolpidem tartrate) sublingual tablet C-IV 4
Slide 5: Intermezzo: first and only prescription sleep aid approved for middle-of-the-night dosing
Intermezzo: the first and only prescription sleep aid approved for middle-of-the-night dosing Indication statement as approved by FDA: – Intermezzo is indicated for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. – Interm
Slide 6: Intermezzo: first and only prescription sleep aid approved for middle-of-the-night dosing
Intermezzo: the first and only prescription sleep aid approved for middle-of-the-night dosing 6
Slide 7: Middle of the night awakening: a major unmet medical need in the insomnia category
Middle of the night (MOTN) awakening: a major unmet medical need in the insomnia category Large U.S. insomnia market – 79 million new and refill prescriptions(1) Insomnia is an under-treated condition (2) – 11 million patients receive Rx(3) – 4x to 6x more are not diagnosed or treated by a physician
Slide 8: Commonly prescribed sleep aids are indicated only for bedtime use
Commonly prescribed sleep aids are indicated only for bedtime use MOTN awakenings typically do not occur every night 7-8 hr sleep aids (Ambien ®, Ambien CR ®, Lunesta®) require bedtime prophylactic dosing to prevent awakenings An ideal therapeutic would: – Be used only at the time patients need help
Slide 9: Intermezzo: first and only sleep aid approved for middle-of-the-night dosing
Intermezzo: the first and only sleep aid approved for middle-of-the night dosing Novel zolpidem formulation – Sublingual tablet – Bicarbonate-carbonate buffers Approved dose – 1.75 mg in women & patients > 65 years – 3.5 mg in non-elderly men Rapidly absorbed in both men and women Effective vs. plac
Slide 10: Intermezzo (zolpidem tartrate) sublingual tablet
Intermezzo” (ZOLPIDEM TARTRATE) sublingual tablet Transcept PHARMACEUTICALS, INC
Slide 11: Significant Rx insomnia market opportunity: each 1% share $130M at branded prices
Significant Rx insomnia market opportunity: each 1% share $130M at branded prices 1 U.S. insomnia market 79 million TRx per year 2 Branded pricing ~$5 to $6 per tablet 3 30 tablets per Rx Average Rx value: $165 Hypothetical market 1% Intermezzo share penetration 790,000 TRx, approx $130M sales (1) I
Slide 12: Intermezzo launch plans
Intermezzo launch plans Initial shipments and physician promotion planned for early April 2012 Purdue plans to invest ~$100M during first 12 months of Intermezzo launch ~275 field representatives in new national sales force devoted exclusively to the promotion of Intermezzo to highest insomnia presc
Slide 13: Purdue commercialization agreement: key Transcept benefits
Purdue commercialization agreement: key Transcept benefits Co-promote option: foundation for a commercial future – Transcept option: co-promote to psychiatrists can begin as early as 1 year and as late as 4.5 years after Purdue launch Royalty structure – Base royalty: mid-teens up to mid 20% level o
Slide 14: Intermezzo managed markets advisory board covering >170M lives
Intermezzo managed markets advisory board with decision makers covering >170M lives Broad formulary access expected Unmet medical need generally recognized by payers – Unique insomnia indication – Low dose used less often – Rapidly absorbed Tier 3 formulary placement anticipated by most plans Utiliz
Slide 15: Intermezzo: intellectual property
Intermezzo: intellectual property
Slide 16: Two U.S. patents issued, additional patent applications pending
Two U.S. patents issued, additional patent applications pending Two issued U.S. patents - 7,682,628 and 7,658,945 – Buffered formulations – Compositions and methods of treating insomnia – Claims require absorption of zolpidem across the oral mucosa – Patents expire no sooner than February 2025 Paten
Slide 17: TO-2061 (low dose ondansetron)
TO-2061 (low dose ondansetron) Proposed indication: adjunctive therapy in adult patients with obsessive compulsive disorder (OCD) not adequately responsive to currently approved OCD medication 17
Slide 18: Significant unmet medical need: OCD patients not responding adequately to approved medication
Significant unmet medical need: OCD patients not responding adequately to approved medication Obsessive Compulsive Disorder – Intrusive thoughts and repetitive actions to reduce distress – Affects 1% to 2% of U.S. adult population, 40% to 50% seek treatment – Significantly impacts everyday life acti
Slide 19: Pilot Study B: improvement measured as % decrease below baseline
Pilot Study B: Improvement measured as % decrease below baseline Pilot Study B, n=21 0% 0% 10% 10% 20% 20% 30% 30% 40% 40% Responders All patients Non-responders 50% 50% Week Week Week Week Week Week Week Week Week Week Week Week 2 4 6 8 10 12 2 4 6 8 10 12 All Patients: n=21 Responders: n=12 of 21
Slide 20: TO-2061: development overview
TO-2061 : development overview 505b2 NDA pathway Phase 2 double blind, placebo controlled study, n 150, complete enrollment est. Fall 2012, top line data est. Q1 2013 Intellectual property – Method of use patent application filed, priority date May 19, 2009 – Ondansetron, up to ~1.5 mg/day – Pending
Slide 21: Financial overview
Financial overview Transcept PHARMA‘ \CEUTICALS, INC.
Slide 22: Financial position
Financial position – Q4 2011 release and teleconference on 3/14/12 at 1:30 PM PT 9/30/11 Cash & investments: $54.1 M Q3 2011 cash burn rate*: $ 1.9 M / month 2/1/12 update Milestone payment recvd (12/21/11): $10.0 M Shares outstanding: 13.9 M Options / warrants / other: 3.6 Total: 17.5 M Employees:
Slide 23: Trademark notices
Intermezzo ® is a registered trademark of Transcept Pharmaceuticals, Inc. Ambien ® and Ambien CR ® are registered trademarks of sanofi-aventis Lunesta ® is a registered trademark of Sunovion Pharmaceuticals Inc. Zofran ® and Paxil ® are registered trademarks of The GlaxoSmithKline Group of Companies
Transcept Pharmaceuticals — Investor Presentation (March 2012) on 6ix